BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Inclusion Criteria

• •Male or female patients with age ≥18 years at screening.
• •Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug.
• •Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomisation):
• •1. Have an involved body surface area (BSA) ≥10% and
• •2. Have a Psoriasis Area and Severity Index (PASI) score ≥12 and
• •3. Have a static Physician Global Assessment (sPGA) score of ≥3.
• •Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the investigator.
• •Must be a candidate for treatment with Stelara® (ustekinumab) according to local label.